Calcium acetate
Sponsors
National Center for Research Resources (NCRR), Nabi Biopharmaceuticals, Romanian Society of Nephrology, Denver Nephrologists, P.C., Gulhane School of Medicine
Conditions
ArteriosclerosisCalcinosisChronic Kidney DiseaseChronic Kidney DiseasesHaemodialyzed PatientsHealthyHealthy VolunteersHyperparathyroidism, Secondary
Early Phase 1
Phase 1
Phase 3
Phase 4
CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients
CompletedNCT00211939
Start: 2005-01-31End: 2007-03-31Updated: 2008-01-08
Sevelamer, FGF-23 and Endothelial Dysfunction in Chronic Kidney Disease (CKD)
CompletedNCT01135615
Start: 2008-01-31End: 2010-05-31Updated: 2011-07-22
Effect of Phosphate Binders on Markers of Vascular Health in Chronic Kidney Disease Stages 3 and 4
TerminatedNCT01277497
Start: 2011-01-31End: 2016-03-31Updated: 2016-01-14
Unknown Phase
Parathyroid Hormone Levels in Relation to the Phosphorus Content of Meals
CompletedNCT00018135
Updated: 2005-06-24
Arterial Stiffness and Calcifications in Haemodialysis Patients on Sevelamer or Calcium Acetate
WithdrawnNCT00364000
Start: 2012-01-31End: 2017-12-31Updated: 2017-12-22
A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphorus in CKD
CompletedNCT00785629
Start: 2009-02-28End: 2011-07-31Updated: 2012-10-30